Modern Strategy for Preclinical Pharmaceutical R&D: Towards the Virtual Research Company

Author:   David Cavalla (Napp Research Centre, Cambridge, UK) ,  J. Flack ,  R. Jennings
Publisher:   John Wiley & Sons Inc
ISBN:  

9780471971177


Pages:   228
Publication Date:   21 March 1997
Format:   Hardback
Availability:   Out of stock   Availability explained
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Our Price $467.95 Quantity:  
Add to Cart

Share |

Modern Strategy for Preclinical Pharmaceutical R&D: Towards the Virtual Research Company


Add your own review!

Overview

"The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small ""biotechnology"" companies and ""research boutiques,"" and possibly even the ""virtual research company"" might play as contractors and collaborators."

Full Product Details

Author:   David Cavalla (Napp Research Centre, Cambridge, UK) ,  J. Flack ,  R. Jennings
Publisher:   John Wiley & Sons Inc
Imprint:   John Wiley & Sons Inc
Dimensions:   Width: 16.30cm , Height: 1.80cm , Length: 24.20cm
Weight:   0.482kg
ISBN:  

9780471971177


ISBN 10:   0471971170
Pages:   228
Publication Date:   21 March 1997
Audience:   College/higher education ,  Professional and scholarly ,  Postgraduate, Research & Scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Out of stock   Availability explained
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

Reviews

Author Information

David Cavalla is an expert on secondary uses for existing drugs, or drug repurposing. He currrently operates through his consultancy, Numedicus Ltd, having worked in drug repurposing for 15 years. Previously he was CEO of Arachnova, and prior to that held various senior positions in pharmaceutical drug discovery at GSK and Napp Research Centre. He has written widely on drug discovery strategy, and is the author of 70 published papers and patents.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

Aorrng

Shopping Cart
Your cart is empty
Shopping cart
Mailing List